560 related articles for article (PubMed ID: 33671606)
1. Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.
Blanchet A; Bourgmayer A; Kurtz JE; Mellitzer G; Gaiddon C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671606
[TBL] [Abstract][Full Text] [Related]
2. TP53 family members and human cancers.
Bénard J; Douc-Rasy S; Ahomadegbe JC
Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
[TBL] [Abstract][Full Text] [Related]
3. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
4. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
6. The dominant-negative interplay between p53, p63 and p73: A family affair.
Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
[TBL] [Abstract][Full Text] [Related]
7. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer.
Tannapfel A; Schmelzer S; Benicke M; Klimpfinger M; Kohlhaw K; Mössner J; Engeland K; Wittekind C
J Pathol; 2001 Sep; 195(2):163-70. PubMed ID: 11592094
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Intra-p53 Family Member Interactions in Human Cancers.
Ferraiuolo M; Di Agostino S; Blandino G; Strano S
Front Oncol; 2016; 6():77. PubMed ID: 27066457
[TBL] [Abstract][Full Text] [Related]
9. Role of the newer p53 family proteins in malignancy.
Irwin MS; Kaelin WG
Apoptosis; 2001; 6(1-2):17-29. PubMed ID: 11321038
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Venkatanarayan A; Raulji P; Norton W; Flores ER
Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
[TBL] [Abstract][Full Text] [Related]
11. The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies.
Chatterjee K; Das P; Chattopadhyay NR; Mal S; Choudhuri T
Heliyon; 2019 Nov; 5(11):e02624. PubMed ID: 31840114
[TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.
Choi HR; Batsakis JG; Zhan F; Sturgis E; Luna MA; El-Naggar AK
Hum Pathol; 2002 Feb; 33(2):158-64. PubMed ID: 11957139
[TBL] [Abstract][Full Text] [Related]
14. Role of p53 family members p73 and p63 in human hematological malignancies.
Alexandrova EM; Moll UM
Leuk Lymphoma; 2012 Nov; 53(11):2116-29. PubMed ID: 22497596
[TBL] [Abstract][Full Text] [Related]
15. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
[TBL] [Abstract][Full Text] [Related]
16. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.
Murray-Zmijewski F; Lane DP; Bourdon JC
Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values.
Bahnassy AA; Zekri AR; Salem SE; Abou-Bakr AA; Sakr MA; Abdel-Samiaa AG; Al-Bradei M
Histol Histopathol; 2014 Feb; 29(2):207-16. PubMed ID: 23996743
[TBL] [Abstract][Full Text] [Related]
18. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
19. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
Orzol P; Holcakova J; Nekulova M; Nenutil R; Vojtesek B; Coates PJ
Histol Histopathol; 2015 May; 30(5):503-21. PubMed ID: 25510918
[TBL] [Abstract][Full Text] [Related]
20. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
